Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT03404193 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03404193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03404193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
January 18, 2018
Completion date
March 5, 2026
Enrollment
235 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, blastic plasmacytoid dendritic cell neoplasm, chronic myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome, recurrent acute biphenotypic leukemia, recurrent acute myeloid leukemia, recurrent blastic plasmacytoid dendritic cell neoplasm, recurrent chronic myelomonocytic leukemia, recurrent mixed phenotype acute leukemia, refractory acute myeloid leukemia, refractory blastic plasmacytoid dendritic cell neoplasm, refractory chronic myelomonocytic leukemia, refractory mixed phenotype acute leukemia